ArticleBMC infectious diseases2013
Frequent detection of 'azole' resistant Candida species among late presenting AIDS patients in northwest Ethiopia.
Article in BMC infectious diseases, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 1 synthesis or guideline pooled it, 127 citations in OpenAlex.
- Global prevalence and trends of fluconazole resistance in non-albicans Candida species: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Symptomatic vulvovaginal candidiasis and antifungal resistance in HIV-1 positive women at Mbarara city health centre IV.Scientific reports · 2025Article
- Dual Mechanisms of Action: Anti-Candida and Anti-Inflammatory Potential ofJournal of fungi (Basel, Switzerland) · 2024Article
- Prevalence of Oropharyngeal Candidiasis and distribution ofResearch square · 2024Article
- Changing Paradigm of Yeast Isolates in HIV-Seropositive Patients with Oropharyngeal Candidiasis (OPC).Cureus · 2024Article
- Tryptophan End-Tagging Confers Antifungal Activity on a Tick-Derived Peptide by Triggering Reactive Oxygen Species Production.ACS omega · 2024Article
- Photoinactivation by UVA radiation and visible light of Candida auris compared to other fungi.Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology · 2024Article
- Prevalence and Antifungal Susceptibility Profile of OralMedicina (Kaunas, Lithuania) · 2022Article
- State of Evidence on Oral Health Problems in Diabetic Patients: A Critical Review of the Literature.Journal of clinical medicine · 2021Review
- Novel Antifungal Activity of Q-Griffithsin, a Broad-Spectrum Antiviral Lectin.Microbiology spectrum · 2021Article
- Molecular identification and antifungal susceptibility testing ofCurrent medical mycology · 2021Article
- Evaluation of antibacterial and acute oral toxicity of Impatiens tinctoria A. Rich root extracts.PloS one · 2021Article
- Article
- Distribution of Candida albicans and non-albicans Candida species isolated in different clinical samples and their in vitro antifungal suscetibity profile in Ethiopia.BMC infectious diseases · 2020Article
- Detection of antifungal drug-resistant andF1000Research · 2020Article
- The Burden of Fungal Infections in Ethiopia.Journal of fungi (Basel, Switzerland) · 2019Review
- Candida sp. Infections in Patients with Diabetes Mellitus.Journal of clinical medicine · 2019Review
- Enhanced antifungal activity of bovine lactoferrin-producing probiotic Lactobacillus casei in the murine model of vulvovaginal candidiasis.BMC microbiology · 2019Article
- K21 Compound, a Potent Antifungal Agent: Implications for the Treatment of Fluconazole-Resistant HIV-AssociatedFrontiers in microbiology · 2019Article
- Oral colonization by Candida species in HIV-positive patients: association and antifungal susceptibility study.Einstein (Sao Paulo, Brazil) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe chronic use of antifungal agents in the treatment of fungal infection in general and oropharyngeal candidiasis mainly in AIDS patient's leads to the selection of strain resistant to these therapies and a shift in the spectrum of Candida species. This study determines the species diversity and in vitro susceptibility of Candida isolates from late presenting AIDS patients in northwest Ethiopia.
methodsTwo hundred and twenty one HIV/AIDS patients were assessed with a standardized evaluation form at enrolment. Oral rinses were cultured on CHROMagar plates at 37°C for 48 hours and Candida species identification were made following standard microbiological techniques. In vitro drug susceptibility tests were made using broth microdilution method.
resultsThe colonization rate of Candida species was found to be 82.3% (177/215). C. albicans was the predominant species isolated from 139 (81%) patients but there was a diversity of other species. C. glabrata was the most frequent non-albicans species isolated in 22.5% (40/177) of the patients followed by C. tropicalis 14.1% (27/177), C. krusei 5.6% (10) and other unidentifiable Candida species 4% (7/177). Recurrent episodes of oropharyngeal candidiasis and previous exposure to antifungal drugs were found to be predisposing factors for colonization by non-albicans species. Irrespective of the Candida species identified 12.2% (11/90), 7.7% (7/90) and 4.7% (4) of the isolates were resistant to fluconazole, ketoconazole and itraconazole, respectively. In contrast, resistance to micafungin, amphotericin B and 5-Fluorocytosine was infrequent.
conclusionHIV/AIDS patients are orally colonized by single or multiple albicans and non- albicans Candida species that are frequently resistant to azoles and occasionally to amphotericin B, 5-Fluorocytosine and micafungin. These highlight the need for national surveillance for examining Candida epidemiology and resistance to antifungal drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.